<bill session="104" type="h" number="3065" updated="2013-07-14T18:48:08-04:00">
  <state datetime="1996-03-12">REFERRED</state>
  <status>
    <introduced datetime="1996-03-12"/>
  </status>
  <introduced datetime="1996-03-12"/>
  <titles>
    <title as="introduced" type="short">Radiopharmaceutical Review Improvement Act of 1996</title>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act to revise the review of radiopharmaceuticals under section 505 of such Act.</title>
  </titles>
  <sponsor id="400576"/>
  <cosponsors>
    <cosponsor id="400050" joined="1996-05-16"/>
    <cosponsor id="400054" joined="1996-03-12"/>
    <cosponsor id="300030" joined="1996-04-15"/>
    <cosponsor id="400106" joined="1996-04-15"/>
    <cosponsor id="300068" joined="1996-03-12"/>
    <cosponsor id="400296" joined="1996-03-13"/>
    <cosponsor id="400391" joined="1996-03-12"/>
    <cosponsor id="400397" joined="1996-03-22"/>
    <cosponsor id="400427" joined="1996-03-13"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="1996-03-12">
      <text>Referred to the House Committee on Commerce.</text>
    </action>
    <action datetime="1996-03-18">
      <text>Referred to the Subcommittee on Health and Environment.</text>
      <committee name="House Committee on Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF04" subcommittee="Health and Environment" name="House Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Drugs"/>
    <term name="Drug utilization"/>
    <term name="Environmental protection"/>
    <term name="Health"/>
    <term name="Medical tests"/>
    <term name="Pharmaceutical research"/>
    <term name="Radiation safety"/>
    <term name="Radioisotopes in medicine"/>
    <term name="Radiotherapy"/>
    <term name="Risk assessment"/>
    <term name="Science, technology, communications"/>
  </subjects>
  <amendments/>
  <summary>3/12/1996--Introduced.
Radiopharmaceutical Review Improvement Act of 1996 - Amends the Federal Food, Drug, and Cosmetic Act (FDCA) to require that the safety and effectiveness of a radiopharmaceutical be determined: (1) weighing the probable health benefit against any probable risk of injury or illness; and (2) taking into account the absence or presence of pharmacological and toxicological activity of the radiopharmaceutical and the estimated absorbed dose. Allows the indications for which a radiopharmaceutical intended for diagnostic purposes is approved to refer to processes, processes common to or present in one or more disease states, or a diagnostic procedure used in the diagnosis of one or more diseases. Requires that, if a radiopharmaceutical is the primary mode of action in a combination of drugs, the persons charged with premarket review of radiopharmaceutical products have primary regulatory jurisdiction.</summary>
</bill>
